Section Arrow
Quote
CRBP.NASDAQ
- Corbus Pharmaceuticals Holdings
Quotes are at least 15-min delayed:2025/07/20 13:16 EDT
Regular Hours
Last
 8.5
+0.04 (+0.47%)
Day High 
8.8196 
Prev. Close
8.46 
1-M High
8.85 
Volume 
62.63K 
Bid
8.5
Ask
8.89
Day Low
8.485 
Open
8.58 
1-M Low
6.72 
Market Cap 
103.52M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 8.1 
20-SMA 7.96 
50-SMA 7.85 
52-W High 61.9 
52-W Low 4.64 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.24/-5.28
Enterprise Value
105.16M
Balance Sheet
Book Value Per Share
10.39
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
NCNANuCana plc0.0477+0.0009+1.92%-- 
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Quotes are at least 15-min delayed：2025/07/20 13:16 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.